BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016; 8(9): 421-438 [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 74] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou ZQ, Zhao JJ, Chen CL, Liu Y, Zeng JX, Wu ZR, Tang Y, Zhu Q, Weng DS, Xia JC. HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma. Mol Carcinog 2019;58:76-87. [PMID: 30182378 DOI: 10.1002/mc.22908] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
2 Zhou ZF, Peng F, Li JY, Ye YB. Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model. Onco Targets Ther 2019;12:7773-84. [PMID: 31571927 DOI: 10.2147/OTT.S222097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Xu F, Zha G, Wu Y, Cai W, Ao J. Overexpressing lncRNA SNHG16 inhibited HCC proliferation and chemoresistance by functionally sponging hsa-miR-93. Onco Targets Ther 2018;11:8855-63. [PMID: 30573973 DOI: 10.2147/OTT.S182005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 12.3] [Reference Citation Analysis]
4 Lima KG, Krause GC, Schuster AD, Catarina AV, Basso BS, De Mesquita FC, Pedrazza L, Marczak ES, Martha BA, Nunes FB, Chiela ECF, Jaeger N, Thomé MP, Haute GV, Dias HB, Donadio MVF, De Oliveira JR. Gallic acid reduces cell growth by induction of apoptosis and reduction of IL-8 in HepG2 cells. Biomedicine & Pharmacotherapy 2016;84:1282-90. [DOI: 10.1016/j.biopha.2016.10.048] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
5 Dietrich P, Gaza A, Wormser L, Fritz V, Hellerbrand C, Bosserhoff AK. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma. Neoplasia 2019;21:257-68. [PMID: 30685691 DOI: 10.1016/j.neo.2018.11.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
6 Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X, Calvisi DF. Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. Front Oncol 2019;9:1412. [PMID: 31921669 DOI: 10.3389/fonc.2019.01412] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
7 Giovannini C, Minguzzi M, Genovese F, Baglioni M, Gualandi A, Ravaioli M, Milazzo M, Tavolari S, Bolondi L, Gramantieri L. Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. Oncotarget 2016;7:39609-26. [PMID: 27167202 DOI: 10.18632/oncotarget.9203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
8 Lu H, Han M, Yuan X, Tursun K, Zhang Y, Li Y, Li Z, Feng S, Zhou L, Pan Z, Wang Q, Han K, Liu S, Cheng J. Role of IL-6-mediated expression of NS5ATP9 in autophagy of liver cancer cells. J Cell Physiol 2018;233:9312-9. [PMID: 29227529 DOI: 10.1002/jcp.26343] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zhou Y, Guo Y, Zhu Y, Sun Y, Li W, Li Z, Wei L. Dual PPARγ/ɑ agonist oroxyloside suppresses cell cycle progression by glycolipid metabolism switch-mediated increase of reactive oxygen species levels. Free Radic Biol Med 2021;167:205-17. [PMID: 33713839 DOI: 10.1016/j.freeradbiomed.2021.02.032] [Reference Citation Analysis]
10 Tang Y, Chen J, Li J, Zheng Y, Zhong X, Huang S, Chen B, Peng B, Zou X, Chen X. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway. Phytomedicine 2021;86:153563. [PMID: 33951569 DOI: 10.1016/j.phymed.2021.153563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Feng B, Zhu Y, Sun C, Su Z, Tang L, Li C, Zheng G. Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1α-mediated epithelial-mesenchymal transition. Int J Biol Macromol 2019;137:32-44. [PMID: 31252022 DOI: 10.1016/j.ijbiomac.2019.06.189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
12 Shi M, Jiang Y, Yang L, Yan S, Wang YG, Lu XJ. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. J Cell Biochem. 2018;119:4711-4716. [PMID: 29278659 DOI: 10.1002/jcb.26650] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
13 Chen J, Huang C, Chen K, Li S, Zhang X, Cheng J, Cai M, Xiao Y. Overexpression of LBH is associated with poor prognosis in human hepatocellular carcinoma. Onco Targets Ther 2018;11:441-8. [PMID: 29403288 DOI: 10.2147/OTT.S152953] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
14 Lu Y, Xu Q, Yin G, Xu W, Jiang H. Resolvin D1 inhibits the proliferation of lipopolysaccharide-treated HepG2 hepatoblastoma and PLC/PRF/5 hepatocellular carcinoma cells by targeting the MAPK pathway. Exp Ther Med 2018;16:3603-10. [PMID: 30233715 DOI: 10.3892/etm.2018.6651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 He XQ, Zhang YF, Yu JJ, Gan YY, Han NN, Zhang MX, Ge W, Deng JJ, Zheng YF, Xu XM. High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway. Tumour Biol 2017;39:1010428317695971. [PMID: 28347229 DOI: 10.1177/1010428317695971] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
16 Wu M, Zhu Q, Chen L, Yan D. Bilious pleuritis due to hepatic microwave ablation: Two illustrative cases and literature review. Medicine (Baltimore) 2020;99:e22763. [PMID: 33126314 DOI: 10.1097/MD.0000000000022763] [Reference Citation Analysis]
17 Chen Y, Wu Y, Zhang X, Zeng H, Liu Y, Wu Q, Chen Y, Zhu G, Pan Q, Jin L, Guo L, Sun F. Angiopoietin-2 (Ang-2) is a useful serum tumor marker for liver cancer in the Chinese population. Clin Chim Acta. 2018;478:18-27. [PMID: 29253494 DOI: 10.1016/j.cca.2017.12.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Chu YD, Lai HY, Pai LM, Huang YH, Lin YH, Liang KH, Yeh CT. The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine. Cell Death Dis 2019;10:240. [PMID: 30858354 DOI: 10.1038/s41419-019-1486-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
19 Swamy SG, Kameshwar VH, Shubha PB, Looi CY, Shanmugam MK, Arfuso F, Dharmarajan A, Sethi G, Shivananju NS, Bishayee A. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Target Oncol 2017;12:1-10. [PMID: 27510230 DOI: 10.1007/s11523-016-0452-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
20 Yee C, McCoy D, Yu J, Losey A, Jordan C, Moore T, Stillson C, Oh HJ, Kilbride B, Roy S, Patel A, Wilson MW, Hetts SW; ChemoFilter Consortium. Endovascular Ion Exchange Chemofiltration Device Reduces Off-Target Doxorubicin Exposure in a Hepatic Intra-arterial Chemotherapy Model. Radiol Imaging Cancer 2019;1:e190009. [PMID: 32300759 DOI: 10.1148/rycan.2019190009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Dietrich P, Hellerbrand C, Bosserhoff A. The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression. Cancers (Basel) 2019;11:E398. [PMID: 30901922 DOI: 10.3390/cancers11030398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Ding Y, Sun Z, Zhang S, Xu Q, Zhou L, Zhou D, Li Y, Han X, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20201479. [PMID: 32697317 DOI: 10.1042/BSR20201479] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wang Y, Xu Y, Yan W, Han P, Liu J, Gong J, Li D, Ding X, Wang H, Lin Z, Tian D, Liao J. CFIm25 inhibits hepatocellular carcinoma metastasis by suppressing the p38 and JNK/c-Jun signaling pathways. Oncotarget 2018;9:11783-93. [PMID: 29545935 DOI: 10.18632/oncotarget.24364] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
24 Prieto-Domínguez N, Ordóñez R, Fernández A, Méndez-Blanco C, Baulies A, Garcia-Ruiz C, Fernández-Checa JC, Mauriz JL, González-Gallego J. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J Pineal Res 2016;61:396-407. [PMID: 27484637 DOI: 10.1111/jpi.12358] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 16.0] [Reference Citation Analysis]
25 Cigliano A, Wang C, Pilo MG, Szydlowska M, Brozzetti S, Latte G, Pes GM, Pascale RM, Seddaiu MA, Vidili G, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice. Oncotarget 2017;8:54149-59. [PMID: 28903330 DOI: 10.18632/oncotarget.16927] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
26 Lin M, Tian MM, Zhang WP, Xu L, Jin P. Predictive values of diffusion-weighted imaging and perfusion-weighted imaging in evaluating the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma. Onco Targets Ther. 2016;9:7029-7037. [PMID: 27895495 DOI: 10.2147/ott.s112555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
27 Commander SJ, Shaw B, Washburn L, Yoeli D, Rana A, Goss JA. A long-term experience with expansion of Milan criteria for liver transplant recipients. Clin Transplant 2018;32:e13254. [DOI: 10.1111/ctr.13254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Liu X, Hu J, Song X, Utpatel K, Zhang Y, Wang P, Lu X, Zhang J, Xu M, Su T, Che L, Wang J, Evert M, Calvisi DF, Chen X. Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E930. [PMID: 31277283 DOI: 10.3390/cancers11070930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
29 Cigliano A, Pilo MG, Li L, Latte G, Szydlowska M, Simile MM, Paliogiannis P, Che L, Pes GM, Palmieri G, Sini MC, Cossu A, Porcu A, Vidili G, Seddaiu MA, Pascale RM, Ribback S, Dombrowski F, Chen X, Calvisi DF. Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. Oncotarget 2017;8:90638-50. [PMID: 29207593 DOI: 10.18632/oncotarget.21469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
30 Yurdacan B, Egeli U, Eskiler GG, Eryilmaz I, Cecener G, Tunca B. The role of usnic acid-induced apoptosis and autophagy in hepatocellular carcinoma. Hum Exp Toxicol 2019;38:201-15. [DOI: 10.1177/0960327118792052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
31 Zheng L, Guo CY, Chen CS, Xiao JC, Hu HT, Cheng HT, Zong DW, Jiang L, Li HL. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study. Oncotarget 2017;8:97613-22. [PMID: 29228637 DOI: 10.18632/oncotarget.18811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Sun L, Liu S, Wang X, Zheng X, Chen Y, Shen H. eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway. J Transl Med 2021;19:216. [PMID: 34016142 DOI: 10.1186/s12967-021-02877-4] [Reference Citation Analysis]
33 Blasco-Algora S, Masegosa-Ataz J, Alonso S, Gutiérrez ML, Fernández-Rodriguez C. Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol 2016;3:e000104. [PMID: 28074149 DOI: 10.1136/bmjgast-2016-000104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
34 王玉霞, 刘贵秋, 刘辉, 张传山. BMP-2在肝细胞癌中表达及与肿瘤血管生成的关系. 世界华人消化杂志 2017; 25(13): 1150-1158 [DOI: 10.11569/wcjd.v25.i13.1150] [Reference Citation Analysis]
35 Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106-117. [PMID: 28174094 DOI: 10.1016/j.pharmthera.2017.02.010] [Cited by in Crossref: 120] [Cited by in F6Publishing: 123] [Article Influence: 30.0] [Reference Citation Analysis]
36 Liu Y, Chen H, Li X, Zhang F, Kong L, Wang X, Bai J, Wu X. PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma. Front Oncol 2021;11:607021. [PMID: 33718159 DOI: 10.3389/fonc.2021.607021] [Reference Citation Analysis]
37 Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Biomed Pharmacother 2019;114:108864. [PMID: 30981107 DOI: 10.1016/j.biopha.2019.108864] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
38 Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle. 2017;16:499-507. [PMID: 28118080 DOI: 10.1080/15384101.2017.1282586] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
39 Hany H, Shalaby A, Al Kashef W, Kandil W, Shahin RA, El-Alfy H, Besheer T, Farag R, Mohamed M. Evaluation of the role of Notch1 expression in hepatic carcinogenesis with clinico-pathological correlation. Pathology 2018;50:730-6. [PMID: 30389219 DOI: 10.1016/j.pathol.2018.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Gan Y, Han N, He X, Yu J, Zhang M, Zhou Y, Liang H, Deng J, Zheng Y, Ge W, Long Z, Xu X. Long non-coding RNA CASC2 regulates cell biological behaviour through the MAPK signalling pathway in hepatocellular carcinoma. Tumour Biol 2017;39:101042831770622. [DOI: 10.1177/1010428317706229] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
41 Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021; 27(17): 2025-2038 [PMID: 34007137 DOI: 10.3748/wjg.v27.i17.2025] [Reference Citation Analysis]
42 Santangelo L, Battistelli C, Montaldo C, Citarella F, Strippoli R, Cicchini C. Functional Roles and Therapeutic Applications of Exosomes in Hepatocellular Carcinoma. Biomed Res Int. 2017;2017:2931813. [PMID: 28265569 DOI: 10.1155/2017/2931813] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
43 Chen Y, Shen Z, Zhi Y, Zhou H, Zhang K, Wang T, Feng B, Chen Y, Song H, Wang R, Chu X. Long non-coding RNA ROR promotes radioresistance in hepatocelluar carcinoma cells by acting as a ceRNA for microRNA-145 to regulate RAD18 expression. Arch Biochem Biophys. 2018;645:117-125. [PMID: 29559320 DOI: 10.1016/j.abb.2018.03.018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 12.7] [Reference Citation Analysis]
44 Shen ZT, Chen Y, Huang GC, Zhu XX, Wang R, Chen LB. Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway. BMC Cancer 2019;19:1075. [PMID: 31703572 DOI: 10.1186/s12885-019-6312-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
45 Fu C, Xu X, Lu W, Nie L, Yin T, Wu D. Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e17412. [PMID: 31626095 DOI: 10.1097/MD.0000000000017412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
46 Yao S, Ye J, Yin M, Yu R. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. Cancer Lett 2020;483:87-97. [PMID: 32268165 DOI: 10.1016/j.canlet.2020.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
47 Zhang X, Wang M, Teng S, Wang D, Li X, Wang X, Liao W, Wang D. Indolyl-chalcone derivatives induce hepatocellular carcinoma cells apoptosis through oxidative stress related mitochondrial pathway in vitro and in vivo. Chemico-Biological Interactions 2018;293:61-9. [DOI: 10.1016/j.cbi.2018.07.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
48 Mizukami Y, Sugawara K, Kira Y, Tsuruta D. Sorafenib stimulates human skin type mast cell degranulation and maturation. J Dermatol Sci 2017;88:308-19. [PMID: 28843624 DOI: 10.1016/j.jdermsci.2017.08.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
49 Zhang LX, Luo PQ, Chen L, Song DD, Xu AM, Xu P, Xu J. Model to Predict Overall Survival in Patients With Hepatocellular Carcinoma After Curative Hepatectomy. Front Oncol 2020;10:537526. [PMID: 33747893 DOI: 10.3389/fonc.2020.537526] [Reference Citation Analysis]
50 Huang S, Zhou D, Li YX, Ming ZY, Li KZ, Wu GB, Chen C, Zhao YN. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3. J Cell Physiol 2019;234:3500-14. [PMID: 30370582 DOI: 10.1002/jcp.26863] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
51 Yang Y, He P, Li N. The Antitumor Potential of Extract of the Oak Bracket Medicinal Mushroom Inonotus baumii in SMMC-7721 Tumor Cells. Evid Based Complement Alternat Med 2019;2019:1242784. [PMID: 31662769 DOI: 10.1155/2019/1242784] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
52 Peng X, Wei F, Hu X. Long noncoding RNA DLGAP1-AS1 promotes cell proliferation in hepatocellular carcinoma via sequestering miR-486-5p. J Cell Biochem 2020;121:1953-62. [PMID: 31633236 DOI: 10.1002/jcb.29430] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
53 Zhang N, Chen X. A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development. Cell Oncol 2020;43:137-53. [DOI: 10.1007/s13402-019-00478-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
54 Yang D, Ji F, Li Y, Jiao Y, Fang X. GPSM2 Serves as an Independent Prognostic Biomarker for Liver Cancer Survival. Technol Cancer Res Treat 2020;19:1533033820945817. [PMID: 32812493 DOI: 10.1177/1533033820945817] [Reference Citation Analysis]
55 Meyers BM, Vogel A, Marotta P, Kavan P, Kamboj L, Pan J, Geadah M, Trueman D, Sabapathy S. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective. Can J Gastroenterol Hepatol 2021;2021:8811018. [PMID: 33681090 DOI: 10.1155/2021/8811018] [Reference Citation Analysis]
56 Chen YL, Lin PY, Ming YZ, Huang WC, Chen RF, Chen PM, Chu PY. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients. BMC Cancer 2017;17:474. [PMID: 28687090 DOI: 10.1186/s12885-017-3460-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
57 Bai Y, Pei W, Zhang X, Zheng H, Hua C, Min J, Hu L, Du S, Gong Z, Gao J, Zhang Y. ApoM is an important potential protective factor in the pathogenesis of primary liver cancer. J Cancer 2021;12:4661-71. [PMID: 34149930 DOI: 10.7150/jca.53115] [Reference Citation Analysis]
58 Dietrich P, Freese K, Mahli A, Thasler WE, Hellerbrand C, Bosserhoff AK. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option. Oncotarget 2018;9:3605-18. [PMID: 29423069 DOI: 10.18632/oncotarget.23188] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
59 Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut 2018;67:1328-41. [DOI: 10.1136/gutjnl-2017-315402] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
60 Sánchez DI, González-Fernández B, San-Miguel B, de Urbina JO, Crespo I, González-Gallego J, Tuñón MJ. Melatonin prevents deregulation of the sphingosine kinase/sphingosine 1-phosphate signaling pathway in a mouse model of diethylnitrosamine-induced hepatocellular carcinoma. J Pineal Res 2017;62. [PMID: 27696512 DOI: 10.1111/jpi.12369] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
61 Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, Cigliano A, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Tao J, Calvisi DF, Chen L, Chen X. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology 2017;66:167-81. [PMID: 28370287 DOI: 10.1002/hep.29183] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 15.3] [Reference Citation Analysis]
62 Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
63 Chen MH, Lu SN, Chen CH, Lin PC, Jiang JK, D'yachkova Y, Lukanowski M, Cheng R, Chen LT. How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers? Cancers (Basel) 2021;13:3536. [PMID: 34298750 DOI: 10.3390/cancers13143536] [Reference Citation Analysis]
64 Zhang L, Wang K, Deng Q, Li W, Zhang X, Liu X. Identification of Key Hydroxymethylated Genes and Transcription Factors Associated with Alpha-Fetoprotein-Negative Hepatocellular Carcinoma. DNA Cell Biol 2019;38:1346-56. [PMID: 31618054 DOI: 10.1089/dna.2019.4689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
65 Vedarethinam V, Dhanaraj K, Ilavenil S, Arasu MV, Choi KC, Al-Dhabi NA, Srisesharam S, Lee KD, Kim da H, Dhanapal T, Sivanesan R, Choi HS, Kim YO. Antitumor Effect of the Mannich Base(1,3-bis-((3-Hydroxynaphthalen-2-yl)phenylmethyl)urea) on Hepatocellular Carcinoma. Molecules 2016;21:E632. [PMID: 27187346 DOI: 10.3390/molecules21050632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
66 Zhu Q, Gong L, Wang J, Tu Q, Yao L, Zhang JR, Han XJ, Zhu SJ, Wang SM, Li YH, Zhang W. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer 2016;16:806. [PMID: 27756250 DOI: 10.1186/s12885-016-2801-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 6.6] [Reference Citation Analysis]
67 Liu Z, Yang D, Li Y, Jiao Y, Lv G. HN1 as a diagnostic and prognostic biomarker for liver cancer. Biosci Rep 2020;40:BSR20200316. [PMID: 32700728 DOI: 10.1042/BSR20200316] [Reference Citation Analysis]
68 Liu H, Li B. The functional role of exosome in hepatocellular carcinoma. J Cancer Res Clin Oncol 2018;144:2085-95. [PMID: 30062486 DOI: 10.1007/s00432-018-2712-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
69 Zakaria N, Mahdzir MA, Yusoff M, Mohd Arshad N, Awang K, Nagoor NH. Cytotoxic Effects of Pinnatane A Extracted from Walsura pinnata (Meliaceae) on Human Liver Cancer Cells. Molecules 2018;23:E2733. [PMID: 30360475 DOI: 10.3390/molecules23112733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
70 Zheng W, Yao M, Qian Q, Sai W, Qiu L, Yang J, Wu W, Dong Z, Yao D. Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. Oncotarget 2017;8:52321-32. [PMID: 28881732 DOI: 10.18632/oncotarget.13674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
71 Mijares MC, Aldahan AS, Gonzalez HH, Jaimes JP. Sorafenib-induced Facial Acneiform Eruption. Cureus 2019;11:e4545. [PMID: 31275769 DOI: 10.7759/cureus.4545] [Reference Citation Analysis]
72 Li Y, Zhang X, Yang X, Liu J, Li L, Ma W, Chen M. Differential effects of ginkgol C17:1 on cisplatin-induced cytotoxicity: Protecting human normal L02 hepatocytes versus sensitizing human hepatoma HepG2 cells. Oncol Lett 2019;17:3181-90. [PMID: 30867748 DOI: 10.3892/ol.2019.9974] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Bort A, Spínola E, Rodríguez-Henche N, Díaz-Laviada I. Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation. Oncotarget 2017;8:87684-98. [PMID: 29152112 DOI: 10.18632/oncotarget.21196] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
74 Guerrini GP, Pinelli D, Marini E, Corno V, Guizzetti M, Zambelli M, Aluffi A, Lincini L, Fagiuoli S, Lucianetti A, Colledan M. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation. Prog Transplant 2018;28:63-9. [PMID: 29251164 DOI: 10.1177/1526924817746686] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]